TL/DR –
Merck stock has seen significant gains over the last few years yet valuation signals are split, with a Discounted Cash Flow (DCF) model indicating the stock is undervalued while market multiples suggest a premium. Over the past five years, Merck has returned 132.6%, changing pricing expectations compared to the beginning of the period. A DCF analysis suggests Merck is undervalued by 38.8%, however, the stock is currently trading on a Price/Earnings ratio of 111.9x, much higher than the pharmaceutical sector average of 16.0x and a peer group around 29.5x, indicating it may be overvalued.
Merck Stock Valuation: A Matter of Perception and Future Cash Flow
The stock of pharmaceutical giant Merck has seen impressive gains in recent times, but the question of its valuation remains ambiguous. While the Discounted Cash Flow (DCF) suggests the stock is undervalued, market multiples hint at an existing premium on its shares. This presents a dichotomy for investors who must balance the lower overall value score with the potentially undervalued intrinsic value.
- Merck’s shares have given a return of 132.6% over the past five years. This growth trajectory alters the valuation perspective compared to earlier years when expectations were lower.
- Future revenue expectations are hinged on oncology combinations around Keytruda and antibody drug conjugates, along with new products such as the oral PCSK9 inhibitor LIPFENDRA. Simultaneously, patent expirations and expanding drug price negotiations could limit investors’ willingness to pay a premium.
- The company’s value score stands at a low 2 out of 6, indicating that it’s not a clear bargain, even though the DCF estimate suggests shares trade about 38.8% below intrinsic value, and multiples screens as overvalued.
The big question now is whether Merck’s recent share gains already reflect the pipeline and product news flow, or if the intrinsic value estimate still points to room for further upside in the long run. Investors can explore other opportunities in the healthcare sector with a solid balance sheet and fundamentals stocks screener (23 results).
Merck: A Cash Flow Perspective
The Discounted Cash Flow (DCF) model assesses Merck’s potential future cash generation and its present value. At present, Merck produces around $16.1b in free cash flow in the last twelve months. The projected future cash flows in the DCF model are expected to grow gradually over the next decade.
Consequently, the DCF model suggests an estimated intrinsic value of $235 per share. This implies the stock trades about 38.8% below this estimate. This gap might be due to the recent advancement of the Medicare drug price negotiation program and Merck’s legal challenge to it.
In conclusion, from a DCF perspective, Merck’s shares appear to be undervalued relative to its projected future cash generation.
Assessment Based on Earnings
Merck’s valuation based on the Price to Earnings (P/E) ratio paints a different picture. Currently, it trades at 111.9x earnings, significantly higher than the pharmaceuticals sector average of 16.0x and a peer group average of 29.5x.
The estimated fair P/E multiple for Merck is around 48.5x considering its size, risk profile, and profitability. With the current valuation far exceeding this, it suggests that investors are already paying a substantial premium for Merck’s oncology pipeline and new launches such as LIPFENDRA, despite policy pressure on pricing.
Based solely on the P/E ratio, Merck’s stock appears to be overvalued compared to both its sector and the tailored fair multiple estimate.
Justifying Merck’s Current Price
The complex valuation of Merck can be unraveled by looking at potential future scenarios for growth, profitability and earnings. Investors are split, with one group optimistic about the pipeline’s potential and the other concerned about policy and Keytruda risk.
According to the bullish perspective, Merck is nearly fairly valued as its late-phase pipeline has tripled since 2021. This is expected to provide a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth.
The bearish view suggests Merck is overvalued by 33%. This is attributed to increasing global pressure on drug pricing, the prospect of government-mandated price cuts, and the potential impact of the Inflation Reduction Act, which could erode future revenue and squeeze net margins.
You can join the debate on Merck’s valuation on our Community page.
Final Thoughts
The verdict on Merck’s valuation is a mixed bag. The DCF model suggests a potential undervaluation, while P/E and other market multiples point towards an overvalued stock that already factors in optimism about the pipeline. This discrepancy, along with a weak overall value profile, suggests that the market is paying a premium for growth, sentiment, and oncology potential. The deciding factor here would be if Merck can translate its pipeline and pricing power into cash generation in line with the optimistic earnings multiple rather than the more cautious market view on policy and patent risk.
—
Read More US Economic News